Patents by Inventor Christopher Charles Stimson

Christopher Charles Stimson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS
    Publication number: 20220395512
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 15, 2022
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Compounds
    Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • KCNQ2-5 channel activator
    Patent number: 10519105
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 31, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
  • TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES
    Publication number: 20190194148
    Abstract: The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 27, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES
    Publication number: 20190177284
    Abstract: The present invention relates to tetrazolyl-containing cyclopropanecarboxamides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES
    Publication number: 20190177279
    Abstract: The present invention relates to carboxylic acid aromatic 1,2-cyclopropylamides of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
  • KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20190127320
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
  • Azetidines as histamine H3 receptor antagonists
    Patent number: 8912176
    Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: December 16, 2014
    Assignee: Evotec AG
    Inventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson
  • AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS
    Publication number: 20120040952
    Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 16, 2012
    Applicant: EVOTEC AG
    Inventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson